Group 1: Company Development and Business Transformation - The company has evolved from focusing on asynchronous motors and brushless/brush DC motors (1995-2005) to a "motor+" strategic transformation, introducing products like magnetic coupling pumps and control components from 2005 to 2025 [1] - By 2025, the company aims to extend its product layout into the smart industry, establishing joint ventures in industrial and humanoid robotics [1] Group 2: Revenue Composition and Future Trends - In 2024, motor products will account for 46.82% of revenue, primarily from brushless/brush DC motors and asynchronous motors, used in industrial equipment and new energy vehicles [2] - Fan products will represent 50.26% of revenue, mainly from external rotor and brushless fans, applied in data centers and thermal management systems for new energy vehicles [2] - Intelligent components and others will make up 2.92% of revenue, including driver assemblies and control systems, indicating a shift towards system integration and globalization [2] Group 3: Market Opportunities and Growth Drivers - The electric motor industry is closely linked to global energy transition, smart upgrades, and green manufacturing trends, suggesting a promising future [2] - The expansion of the new energy vehicle market and the increasing demand for thermal management systems are expected to enhance market share for the company's heat pipe systems [2] - Continuous development in communication technologies like 5G will drive demand for communication base stations and data centers, providing further business expansion opportunities [2] - The rapid growth of the robotics industry is anticipated to become a significant business growth point for the company, alongside automotive electronics and healthcare sectors [2]

证券代码：870976 证券简称：视声智能 公告编号：2025-057 □媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 广州视声智能股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 投资者关系活动类别 □特定对象调研 □业绩说明会 1 桂私募基金投资有限公司、瑞民私募证券投资基金管理有限公司、点石成鑫资产 管理有限公司、星允投资管理有限公司、同巨投资有限公司、青创伯乐投资有限 公司（以上排名不分先后） 上市公司接待人员：广州视声智能股份有限公司董事会秘书兼财务总监董浩 先生 三、 投资者关系活动主要内容 本次交流活动，对广州视声智能股份有限公司（以下简称"公司"）基本情 况进行了介绍，并就投资者关心的问题进行了沟通与交流，主要问题及回复情况 如下： 问题 1：公司一季度利润增长的原因是什么？目前在手订单情况如何？ √其他 （线上会议） 二、 投资者关系活动情况 活动时间：2025 年 6 月 6 日 活动地点：线上调研 参会单位及人员：开源证券股份 ...

Group 1: Financial Performance - The company's profit has significantly improved year-on-year due to three main factors: 1. The conductive film business structure optimization led to revenue growth, with the gaming touch button field generating revenue of 98.73 million, up 22.83% year-on-year [1] 2. The sales of dimmable conductive films in automotive applications reached 66.95 million, increasing by 122.70% year-on-year [1] 3. The 2A/3A optical film products achieved revenue of 29.45 million, a year-on-year growth of 104.19% [2] Group 2: Product Development and Market Trends - The embedded in-cell technology has improved the thickness by 0.3mm and increased light transmittance by 15%, with the yield rate rising from 65% three years ago to 88% in 2024, driving the penetration rate of LCD mobile phones to over 75% [2] - The company has established four major technology platforms for dimmable conductive films, focusing on automotive applications such as sunroofs and side windows [2][3] Group 3: Competitive Landscape and Future Outlook - The main competitors in the dimmable conductive film market include EC, SPD, LC, and PDLC technologies, with the company primarily focusing on EC electrochromic technology [3] - The OCA optical adhesive product has seen a revenue of 158 million, growing by 21.3% year-on-year, but has not yet achieved profitability due to market price competition and high R&D costs [5]

Group 1: Company Overview and Product Offerings - The company focuses on vehicle networking smart terminals, including TBOX, eCall, battery monitoring devices, and battery swapping systems, with potential for more products in the future [2] - eCall is a critical vehicle emergency call system that enhances rescue efficiency and reduces accident fatalities, triggered either automatically or manually [4] - The company provides digital battery management solutions for clients in the new energy sector, enabling comprehensive lifecycle management of batteries [6] Group 2: Research and Development - The company emphasizes forward-looking R&D, aligning with industry trends and customer needs, resulting in a steady increase in R&D expenditure [2] - The R&D system is built on a "platform and modular" approach, allowing for rapid product development and customization based on client requirements [2][3] Group 3: Market Position and Standards - The national standard for eCall (AECS) was released on April 25, 2025, with various countries promoting eCall systems as a vital safety feature [5] - The company holds a leading position in the eCall market, having received the first EU eCall certification in China and the first NG eCall certification globally [7] Group 4: Production Capacity and Flexibility - The company operates a flexible production line capable of meeting automotive-grade product demands, with both in-house and outsourced manufacturing for non-core components [8] - Future production capacity will be adjusted based on market conditions to ensure responsiveness to demand [8] Group 5: TBOX Functionality - TBOX serves as a core controller for vehicle information interaction, enabling communication with various vehicle systems and providing essential connectivity for smart vehicle functions [10]

Group 1: Financial Performance - In Q1 2025, the company achieved revenue of ¥247,732,813.14, a decrease of 7.17% compared to ¥266,864,471.78 in the same period last year [3] - Net profit attributable to shareholders was ¥14,448,489.46, up 298.35% from ¥3,627,075.29 year-on-year [3] - The company aims to turn a profit in 2025, leveraging sales growth in blood dialysis equipment and consumables [2] Group 2: Product Development and Innovation - New products launched in 2024 include a polypropylene (PP) blood dialysis device and specialized dialysis concentrates, with two additional products showcased in April 2025 [4] - The company focuses on developing intelligent medical devices that address clinical pain points, enhancing product differentiation [5][6] Group 3: Market Opportunities and Strategies - The blood dialysis market in China has approximately 916,600 patients, with a compound annual growth rate exceeding 10% [8] - Recent government policies promoting equipment upgrades are expected to boost demand for the company's monitoring devices and blood dialysis equipment [7] - The company is actively exploring opportunities in the overseas blood dialysis market, although current sales remain limited [9] Group 4: Future Directions - In 2025, the company will concentrate on high-end, intelligent, and IoT-enabled products, aiming to enhance market penetration in critical care and anesthesia [12] - The company plans to strengthen its supply chain and production efficiency while embracing centralized procurement policies to improve operational effectiveness [12]

Group 1: Financial Performance - In Q1 2025, the company achieved a revenue growth of 17% in medical devices and 10% in professional pharmacy (DTP) sales [2] - The total revenue from the traditional Chinese medicine sector reached 14.86 billion CNY in 2024, with over 140 subsidiaries involved in this business [5] Group 2: Strategic Developments - The company has established partnerships with over 400 medical institutions under the General Group, opening accounts in 102 of them, including 86 grade hospitals [2] - The "300 Cities" strategic plan has been implemented, covering 160 cities across 31 provinces and regions in China [4] Group 3: Future Plans - The company aims to deepen its investment and acquisition efforts in 2025 to strengthen its regional network and enhance competitive advantages [4] - Future developments in the traditional Chinese medicine sector will focus on building a comprehensive industry chain, including smart Chinese medicine pharmacies and specialty Chinese medicine pieces [5] Group 4: Marketing and Sales Initiatives - The company has formed a national marketing team to enhance service capabilities, achieving sales in 31 provinces through its CSO projects [6] - New product promotions have been successfully launched, including several proprietary drugs [6]

Group 1: Company Overview - The company specializes in the R&D, production, and sales of high-end equipment key castings, positioning itself as a high-tech enterprise with independent R&D and innovation capabilities [2] - It has over 30 years of experience in the casting industry and aims to become a leading enterprise in the global high-end equipment sector, promoting "craftsmanship spirit and green intelligent manufacturing" [2] - The company is one of the few domestic manufacturers that master both high-performance ductile iron and aluminum casting core technologies, adopting a diversified development model involving wind power, electric power, and medical equipment [2] Group 2: Production Capacity and Planning - The company is currently constructing a "30,000 tons annual production capacity for key precision components" project, with some equipment expected to be installed by Q3 2025 [3] - Production capacity will be adjusted based on industry changes, market developments, and customer orders, with a focus on increasing domestic and international customer development [3] - The company aims to enhance its sales level by aligning closely with customer needs and industry trends, while continuously integrating customer resources and supply chain advantages [3] Group 3: Market Performance and Customer Base - In the wind power sector, the company has concentrated domestic clients, with significant sales growth in Q1 2025 due to favorable policies, indicating a positive outlook for the wind power industry this year [3] - The overseas market shows stable order volumes from long-term partners, with a strong focus on business cooperation and seizing market opportunities [3] - Key clients in the pump and valve sector include Grundfos, while Siemens Medical and Neusoft Medical are major clients in the medical equipment field; the company plans to maintain existing relationships while expanding its customer base [3]

Group 1: Investor Relations Activities - The investor relations activity involved a specific audience survey with participation from various investment institutions, including Tianfeng Securities and China Acquisition Group [1] - The event took place on June 10, 2025, in Shenzhen [1] Group 2: Strategic Investment and Financial Goals - Shenzhen Energy's environmental subsidiary successfully attracted five leading domestic investment institutions as strategic investors, raising RMB 5 billion by March 2025 [2] - The raised funds will focus on enhancing technological innovation and expanding light asset businesses, aiming to establish a strong brand presence both domestically and internationally [2] Group 3: Current and Future Projects - The company has an ongoing coal power project in Baoding with a capacity of 660,000 kW and has approved but not yet constructed projects, including the Ma Wan 2×66 MW coal upgrade project [2] - As of Q1 2025, all operational gas power plants, except for two specific plants, have achieved profitability [2] Group 4: Policy Response and Market Adaptation - The company is closely monitoring the implementation details of the 136 Document issued on January 27, 2025, which promotes market-oriented pricing for renewable energy [2] - The company is enhancing its capabilities in investment decision-making and market forecasting to adapt to the new policy environment [2]

Group 1: Financial Performance - In Q1 2025, the company achieved a revenue of 385 million CNY, representing a year-on-year growth of 5.23% [2] - The pesticide revenue was 249 million CNY, with a growth of 2.05%, while fertilizer revenue reached 120 million CNY, growing by 14.28% [2] - The overall gross margin was 46.25%, an increase of 2.42% compared to the previous year [2] - The net profit attributable to shareholders was 79 million CNY, reflecting a year-on-year increase of 16% [2] Group 2: Growth Drivers - The main reasons for sustained growth include the expanded influence of comprehensive crop regulation solutions, increased promotional areas, and enhanced marketing efforts for key products [3] - Price recovery in certain pesticides and fertilizers has stimulated consumer demand [3] - Rising grain prices have encouraged farmers to invest more in agricultural inputs [3] Group 3: Competitive Advantages - The company holds 142 registration certificates for plant growth regulators, accounting for approximately 8% of the total in China, making it the largest in terms of both registration and sales [3] - The establishment of the Crop Quality Regulation Technology Research Institute in 2017 has bolstered technical support, with over 100 researchers conducting trials nationwide [3] - The company has built a strong brand and distribution network, with over 6,200 dealers and more than 20 logistics warehouses across the country [3] Group 4: Market Outlook - Fluctuations in grain prices have a limited impact on the demand for essential agricultural inputs like pesticides and fertilizers [3] - The company plans to strengthen market promotion and expand into untapped markets to further increase revenue [3]

Company Overview - Zhejiang Yongtai Technology Co., Ltd. was established in 1999 and listed in 2009, headquartered in Taizhou, Zhejiang Province. It is a global leader in fluorine fine chemicals, covering both inorganic and organic fluorochemical industries [2][3]. - The company has multiple production bases in Zhejiang, Inner Mongolia, Fujian, and Guangdong, with sufficient existing, under-construction, and planned capacities to support future growth [2]. Financial Performance - In 2024, the company achieved a revenue of CNY 458,939.78 million, representing an 11.18% year-on-year growth. The net profit, after deducting non-recurring items, showed a loss reduction of 36.26% [3]. - The lithium battery materials segment saw a significant improvement, with a gross margin increase of 23.07 percentage points. The plant protection segment's revenue grew by 91.79%, enhancing market competitiveness [3]. - In Q1 2025, the company reported a revenue of CNY 105,995.92 million and a net profit of CNY 1,057.75 million [3]. Lithium Battery Technology Development - The company is focusing on the strategic development of long-duration lithium battery technology, emphasizing collaboration in research and development to enhance technical maturity [4]. - The timeline for industrialization of this technology is uncertain and will depend on various factors, including technical validation and market conditions [5]. Lithium Battery Materials Segment - The profitability of the lithium battery materials segment is influenced by raw material price fluctuations and supply-demand dynamics. The company has implemented cost-reduction and efficiency-enhancing measures [7]. - The production capacity for liquid dual fluorine (LiFSI) is currently 67,000 tons per year, with a steady increase in utilization and a reduction in production costs [9]. Market Outlook and Strategies - The company anticipates that the price trends for lithium battery materials will be affected by market supply-demand, raw material costs, and industry policies, making future predictions challenging [8]. - The company is actively expanding its market share in the lithium battery materials sector and enhancing its competitive edge [7]. Pharmaceutical and Plant Protection Segments - In the pharmaceutical sector, the company aims to develop high-value-added formulation products and has established a dedicated marketing team covering 26 provinces and regions [11]. - The plant protection business includes a comprehensive product layout covering pesticide intermediates, active ingredients, and formulations, with a focus on international trade [11].